Exicure (XCUR) Competitors $10.73 +0.76 (+7.62%) Closing price 03:59 PM EasternExtended Trading$11.00 +0.27 (+2.52%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. AURA, PVLA, ACB, CMPX, TSVT, TERN, AVIR, DBVT, SLDB, and MNPRShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Aura Biosciences (AURA), Palvella Therapeutics (PVLA), Aurora Cannabis (ACB), Compass Therapeutics (CMPX), 2seventy bio (TSVT), Terns Pharmaceuticals (TERN), Atea Pharmaceuticals (AVIR), DBV Technologies (DBVT), Solid Biosciences (SLDB), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Aura Biosciences Palvella Therapeutics Aurora Cannabis Compass Therapeutics 2seventy bio Terns Pharmaceuticals Atea Pharmaceuticals DBV Technologies Solid Biosciences Monopar Therapeutics Aura Biosciences (NASDAQ:AURA) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Is AURA or XCUR more profitable? Aura Biosciences' return on equity of -41.57% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -41.57% -36.43% Exicure N/A -190.90%-36.75% Does the media prefer AURA or XCUR? In the previous week, Aura Biosciences had 1 more articles in the media than Exicure. MarketBeat recorded 2 mentions for Aura Biosciences and 1 mentions for Exicure. Exicure's average media sentiment score of 1.43 beat Aura Biosciences' score of 0.75 indicating that Exicure is being referred to more favorably in the news media. Company Overall Sentiment Aura Biosciences Positive Exicure Positive Does the MarketBeat Community prefer AURA or XCUR? Aura Biosciences received 17 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 61.90% of users gave Aura Biosciences an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformAura BiosciencesOutperform Votes2661.90% Underperform Votes1638.10% ExicureOutperform Votes947.37% Underperform Votes1052.63% Do analysts prefer AURA or XCUR? Aura Biosciences currently has a consensus price target of $22.75, suggesting a potential upside of 269.92%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, AURA or XCUR? Aura Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.74, meaning that its share price is 274% more volatile than the S&P 500. Which has higher valuation & earnings, AURA or XCUR? Exicure has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$76.41M-$1.75-3.51Exicure$500K135.58-$16.91M-$4.81-2.23 Do institutionals and insiders hold more shares of AURA or XCUR? 96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by insiders. Comparatively, 3.9% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryAura Biosciences beats Exicure on 13 of the 17 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.79M$6.84B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-5.187.4422.6818.83Price / Sales135.58257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book6.136.576.794.33Net Income-$16.91M$143.14M$3.22B$247.97M7 Day Performance-0.65%3.59%2.44%2.71%1 Month Performance-12.76%6.00%3.78%3.37%1 Year Performance2,041.72%-2.03%17.05%5.80% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure2.0215 of 5 stars$10.73+7.6%N/A+1,854.9%$67.79M$500,000.00-5.1850Short Interest ↓Positive NewsGap UpAURAAura Biosciences2.0159 of 5 stars$5.51+2.4%$22.75+312.9%-20.7%$276.74MN/A-3.1850Upcoming EarningsShort Interest ↑News CoveragePVLAPalvella Therapeutics3.4509 of 5 stars$24.57-3.2%$44.43+80.8%N/A$270.74M$42.81M-2.03N/AAnalyst ForecastACBAurora Cannabis0.6676 of 5 stars$4.68-2.7%N/A-35.5%$263.08M$320.81M93.621,340News CoverageGap UpCMPXCompass Therapeutics3.4057 of 5 stars$1.90-2.1%$13.38+603.9%+15.9%$262.74M$850,000.00-5.1320Short Interest ↑Analyst RevisionTSVT2seventy bio1.7599 of 5 stars$4.99+0.2%$5.60+12.2%+8.3%$261.17M$37.86M-2.68440Short Interest ↑News CoverageTERNTerns Pharmaceuticals4.2979 of 5 stars$2.94+0.7%$18.38+525.0%-29.9%$256.66MN/A-2.4940News CoveragePositive NewsAVIRAtea Pharmaceuticals3.2006 of 5 stars$2.96+2.4%$6.00+102.7%-22.3%$253.15MN/A-1.4370News CoveragePositive NewsDBVTDBV Technologies3.2838 of 5 stars$9.17+7.5%$22.50+145.4%+24.8%$251.17M$15.73M-2.0480Upcoming EarningsAnalyst ForecastNews CoverageSLDBSolid Biosciences3.8832 of 5 stars$3.23-2.1%$15.67+385.0%-61.7%$250.30M$8.09M-1.06100News CoverageMNPRMonopar Therapeutics1.8348 of 5 stars$40.81-4.4%$55.33+35.6%+1,227.7%$249.47MN/A-20.7210Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Aura Biosciences Alternatives Palvella Therapeutics Alternatives Aurora Cannabis Alternatives Compass Therapeutics Alternatives 2seventy bio Alternatives Terns Pharmaceuticals Alternatives Atea Pharmaceuticals Alternatives DBV Technologies Alternatives Solid Biosciences Alternatives Monopar Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XCUR Stock Free XCUR Stock Alerts